This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mukai, S. Articles by Plautz, G. E. Search for Related Content PubMed PubMed Citation Articles by Mukai, S. Articles by Plautz, G. E.

Infiltration of Tumors by Systemically Transferred Tumor-Reactive T Lymphocytes Is Required for Antitumor Efficacy¹

Center for Surgery Research/FF50, The Cleveland Clinic Foundation, Cleveland, Ohio 44195

The systemic transfer of ex vivo-activated tumor-sensitized T lymphocytes can mediate immunologically specific regression of established tumors. However, it has not been conclusively established whether the infiltration of systemically transferred T cells into metastases is required for their effector function. In this study, T cells from lymph nodes draining the murine fibrosarcoma MCA 205 cells were activated ex vivo with anti-CD3 monoclonal antibody and interleukin-2. During the final 24 h of culture, the T cells were treated with pertussis toxin (PTX) to inhibit signaling through G protein-coupled chemokine receptors required for diapedesis. Systemically transferred PTX-treated cells did not have any therapeutic efficacy against 3-day established pulmonary metastases. This lack of efficacy correlated with their failure to infiltrate the tumor parenchyma. However, PTX-treated cells responded to tumor antigen stimulation with IFN- secretion in vitro. More importantly, PTX-treated effector T cells prevented tumor growth when they were admixed with tumor cells and inoculated s.c. These results demonstrate that systemically transferred tumor-reactive T lymphocytes need to infiltrate the tumor parenchyma through the endothelium to initiate tumor regression, but PTX-sensitive proteins are not required for either antigen recognition or effector functions.

This article has been cited by other articles:

				K. I. Al-Shibli, T. Donnem, S. Al-Saad, M. Persson, R. M. Bremnes, and L.-T. Busund Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non-Small Cell Lung Cancer Clin. Cancer Res., August 15, 2008; 14(16): 5220 - 5227. [Abstract] [Full Text] [PDF]

				S. B. J. Wong, R. Bos, and L. A. Sherman Tumor-Specific CD4+ T Cells Render the Tumor Environment Permissive for Infiltration by Low-Avidity CD8+ T Cells J. Immunol., March 1, 2008; 180(5): 3122 - 3131. [Abstract] [Full Text] [PDF]

				A. A. Lugade, E. W. Sorensen, S. A. Gerber, J. P. Moran, J. G. Frelinger, and E. M. Lord Radiation-Induced IFN-{gamma} Production within the Tumor Microenvironment Influences Antitumor Immunity J. Immunol., March 1, 2008; 180(5): 3132 - 3139. [Abstract] [Full Text] [PDF]

				C. E. Brown, R. P. Vishwanath, B. Aguilar, R. Starr, J. Najbauer, K. S. Aboody, and M. C. Jensen Tumor-Derived Chemokine MCP-1/CCL2 Is Sufficient for Mediating Tumor Tropism of Adoptively Transferred T Cells J. Immunol., September 1, 2007; 179(5): 3332 - 3341. [Abstract] [Full Text] [PDF]

				L.-X. Wang, S. Shu, M. L. Disis, and G. E. Plautz Adoptive transfer of tumor-primed, in vitro activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response Blood, June 1, 2007; 109(11): 4865 - 4876. [Abstract] [Full Text] [PDF]

				A. Boissonnas, L. Fetler, I. S. Zeelenberg, S. Hugues, and S. Amigorena In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor J. Exp. Med., February 19, 2007; 204(2): 345 - 356. [Abstract] [Full Text] [PDF]

				L. Bracci, F. Moschella, P. Sestili, V. La Sorsa, M. Valentini, I. Canini, S. Baccarini, S. Maccari, C. Ramoni, F. Belardelli, et al. Cyclophosphamide Enhances the Antitumor Efficacy of Adoptively Transferred Immune Cells through the Induction of Cytokine Expression, B-Cell and T-Cell Homeostatic Proliferation, and Specific Tumor Infiltration Clin. Cancer Res., January 15, 2007; 13(2): 644 - 653. [Abstract] [Full Text] [PDF]

				X. Yang, Y. Chu, Y. Wang, R. Zhang, and S. Xiong Targeted in vivo expression of IFN-{gamma}-inducible protein 10 induces specific antitumor activity J. Leukoc. Biol., December 1, 2006; 80(6): 1434 - 1444. [Abstract] [Full Text] [PDF]

				L.-X. Wang, S. Shu, and G. E. Plautz Host Lymphodepletion Augments T Cell Adoptive Immunotherapy through Enhanced Intratumoral Proliferation of Effector Cells Cancer Res., October 15, 2005; 65(20): 9547 - 9554. [Abstract] [Full Text] [PDF]

				L. M. Liau, R. M. Prins, S. M. Kiertscher, S. K. Odesa, T. J. Kremen, A. J. Giovannone, J.-W. Lin, D. J. Chute, P. S. Mischel, T. F. Cloughesy, et al. Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment Clin. Cancer Res., August 1, 2005; 11(15): 5515 - 5525. [Abstract] [Full Text] [PDF]

				M. Gough, M. Crittenden, U. Thanarajasingam, L. Sanchez-Perez, J. Thompson, D. Jevremovic, and R. Vile Gene Therapy to Manipulate Effector T Cell Trafficking to Tumors for Immunotherapy J. Immunol., May 1, 2005; 174(9): 5766 - 5773. [Abstract] [Full Text] [PDF]

				Q. Li, A. L. Carr, E. J. Donald, J. J. Skitzki, R. Okuyama, L. M. Stoolman, and A. E. Chang Synergistic Effects of IL-12 and IL-18 in Skewing Tumor-Reactive T-Cell Responses Towards a Type 1 Pattern Cancer Res., February 1, 2005; 65(3): 1063 - 1070. [Abstract] [Full Text] [PDF]

				D. C. Palmer, S. Balasubramaniam, K.-i. Hanada, C. Wrzesinski, Z. Yu, S. Farid, M. R. Theoret, L. N. Hwang, C. A. Klebanoff, L. Gattinoni, et al. Vaccine-Stimulated, Adoptively Transferred CD8+ T Cells Traffic Indiscriminately and Ubiquitously while Mediating Specific Tumor Destruction J. Immunol., December 15, 2004; 173(12): 7209 - 7216. [Abstract] [Full Text] [PDF]

				J. Skitzki, R. A. Craig, R. Okuyama, R. N. Knibbs, K. McDonagh, A. E. Chang, and L. M. Stoolman Donor Cell Cycling, Trafficking, and Accumulation during Adoptive Immunotherapy for Murine Lung Metastases Cancer Res., March 15, 2004; 64(6): 2183 - 2191. [Abstract] [Full Text] [PDF]

				L. A. O'Mara and P. M. Allen Pulmonary Tumors Inefficiently Prime Tumor-Specific T Cells J. Immunol., January 1, 2004; 172(1): 310 - 317. [Abstract] [Full Text] [PDF]

				T. Calzascia, W. Di Berardino-Besson, R. Wilmotte, F. Masson, N. d. Tribolet, P.-Y. Dietrich, and P. R. Walker Cutting Edge: Cross-Presentation as a Mechanism for Efficient Recruitment of Tumor-Specific CTL to the Brain J. Immunol., September 1, 2003; 171(5): 2187 - 2191. [Abstract] [Full Text] [PDF]

				L. Peng, J. Kjaergaard, G. E. Plautz, M. Awad, J. A. Drazba, S. Shu, and P. A. Cohen Tumor-Induced L-Selectinhigh Suppressor T Cells Mediate Potent Effector T Cell Blockade and Cause Failure of Otherwise Curative Adoptive Immunotherapy J. Immunol., November 1, 2002; 169(9): 4811 - 4821. [Abstract] [Full Text] [PDF]

				D. Duguay, F. Mercier, J. Stagg, D. Martineau, J. Bramson, M. Servant, R. Lin, J. Galipeau, and J. Hiscott In Vivo Interferon Regulatory Factor 3 Tumor Suppressor Activity in B16 Melanoma Tumors Cancer Res., September 15, 2002; 62(18): 5148 - 5152. [Abstract] [Full Text] [PDF]

				L.-X. Wang, B.-G. Chen, and G. E. Plautz Adoptive Immunotherapy of Advanced Tumors with CD62 L-Selectinlow Tumor-Sensitized T Lymphocytes Following Ex Vivo Hyperexpansion J. Immunol., September 15, 2002; 169(6): 3314 - 3320. [Abstract] [Full Text] [PDF]

				H. Huang, F. Li, J. R. Gordon, and J. Xiang Synergistic Enhancement of Antitumor Immunity with Adoptively Transferred Tumor-specific CD4+ and CD8+ T Cells and Intratumoral Lymphotactin Transgene Expression Cancer Res., April 1, 2002; 62(7): 2043 - 2051. [Abstract] [Full Text] [PDF]

				R. Ganss, E. Ryschich, E. Klar, B. Arnold, and G. J. Hammerling Combination of T-Cell Therapy and Trigger of Inflammation Induces Remodeling of the Vasculature and Tumor Eradication Cancer Res., March 1, 2002; 62(5): 1462 - 1470. [Abstract] [Full Text] [PDF]

				J. Kjaergaard, L. Peng, P. A. Cohen, J. A. Drazba, A. D. Weinberg, and S. Shu Augmentation Versus Inhibition: Effects of Conjunctional OX-40 Receptor Monoclonal Antibody and IL-2 Treatment on Adoptive Immunotherapy of Advanced Tumor J. Immunol., December 1, 2001; 167(11): 6669 - 6677. [Abstract] [Full Text] [PDF]

				M. Saio, S. Radoja, M. Marino, and A. B. Frey Tumor-Infiltrating Macrophages Induce Apoptosis in Activated CD8+ T Cells by a Mechanism Requiring Cell Contact and Mediated by Both the Cell-Associated Form of TNF and Nitric Oxide J. Immunol., November 15, 2001; 167(10): 5583 - 5593. [Abstract] [Full Text] [PDF]

				K. Tanigawa, N. Takeshita, R. A. Craig, K. Phillips, R. N. Knibbs, A. E. Chang, and L. M. Stoolman Tumor-Specific Responses in Lymph Nodes Draining Murine Sarcomas Are Concentrated in Cells Expressing P-Selectin Binding Sites J. Immunol., September 15, 2001; 167(6): 3089 - 3098. [Abstract] [Full Text] [PDF]

				C. M. Cairns, J. R. Gordon, F. Li, M. E. Baca-Estrada, T. Moyana, and J. Xiang Lymphotactin Expression by Engineered Myeloma Cells Drives Tumor Regression: Mediation by CD4+ and CD8+ T Cells and Neutrophils Expressing XCR1 Receptor J. Immunol., July 1, 2001; 167(1): 57 - 65. [Abstract] [Full Text] [PDF]

				K. Schumacher, W. Haensch, C. Röefzaad, and P. M. Schlag Prognostic Significance of Activated CD8+ T Cell Infiltrations within Esophageal Carcinomas Cancer Res., May 1, 2001; 61(10): 3932 - 3936. [Abstract] [Full Text]

				G. E. Plautz, S. Mukai, P. A. Cohen, and S. Shu Cross-Presentation of Tumor Antigens to Effector T Cells Is Sufficient to Mediate Effective Immunotherapy of Established Intracranial Tumors J. Immunol., October 1, 2000; 165(7): 3656 - 3662. [Abstract] [Full Text] [PDF]

				G. E. Plautz, D. W. Miller, G. H. Barnett, G. H. J. Stevens, S. Maffett, J. Kim, P. A. Cohen, and S. Shu T Cell Adoptive Immunotherapy of Newly Diagnosed Gliomas Clin. Cancer Res., June 1, 2000; 6(6): 2209 - 2218. [Abstract] [Full Text]